| Patient | John Henry Holliday |
|---|---|
| Date of birth | 2004-08-14 |
| Identifiers | MRN HR-NI007-SYN; SSN (made up) 000-07-8153 |
| Document date | 2026-03-17 |
| Author | Martin Beaumont, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week review: susceptibility results, release from isolation, and liver monitoring. [S]
Mr. Holliday returns five weeks into treatment. The isolate is susceptible to isoniazid, rifampin, pyrazinamide, and ethambutol, and ethambutol was stopped a week ago when the result arrived. The three sputum smears collected in the third week were negative, and with his clinical improvement and more than two weeks of treatment he was released from home isolation two weeks ago and returned to work the following week. His cough is now occasional and dry, and the night sweats have stopped. He has taken every dose by video. He has no nausea now, no yellowing, dark urine, abdominal pain, numbness, or vision change. He has not had a drink in three weeks and has met his counselor twice. His roommate's first blood test was negative and will be repeated by the health department. [S]
| Element | Detail |
|---|---|
| Susceptibility | Susceptible to all four first-line drugs; ethambutol stopped a week ago |
| Infection control | Three negative smears; released from isolation and back at work |
| Symptoms | Occasional dry cough; no night sweats |
| Alcohol | None for three weeks; two counseling sessions |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Occasional dry cough; no sputum or blood |
| Constitutional | Negative | No fever or night sweats; appetite good |
| Gastrointestinal | Negative | No nausea, abdominal pain, or jaundice |
| Psychiatric | Negative | Mood better since returning to work; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 2026-02-12 to 2026-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 2026-02-12 to 2026-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-17 | Body height | 178 | cm | S |
| 2026-03-17 | Body weight | 61 | kg | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-03-17 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-03-17 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-17 | Heart rate | 84 | /min | S |
| 2026-03-17 | Respiratory rate | 16 | /min | S |
| 2026-03-17 | Body temperature | 36.8 | Cel | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 7-56 U/L | Normal | S |
| 2026-03-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 47 | U/L | 10-40 U/L | High | S |
| 2026-03-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-03-17 | Total score [AUDIT-C] | 2 | {score} | S |
Vital signs recorded on 2026-03-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 61.0 kg; temperature 36.8 °C |
| Eyes | No icterus |
| Respiratory | A few crackles at the right apex; no bronchial breathing |
| Abdomen | Soft; liver not enlarged or tender |
| Neurological | Normal sensation in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed | F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | Occasional dry cough only |
| Examination | Weight | At least monthly during treatment | Completed today | 61.0 kg, up 3.0 kg since diagnosis |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | None |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 52 U/L normal, AST 47 U/L slightly high, bilirubin 0.8 mg/dL normal; no symptoms |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Not indicated | Ethambutol stopped a week ago, after normal checks at baseline and two weeks |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Completed today | Susceptible to isoniazid, rifampin, pyrazinamide, and ethambutol |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Three smears in the third week negative; cultures from those samples pending |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | All doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy |
| Self-management | Home isolation and the criteria for release | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Release criteria met two weeks ago; back at work, with the health department's agreement |
| Referral | Contact investigation (household, coworkers, patients) | Led by the health department, from diagnosis | Referred | In progress with the health department |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 2 for the past month; none in three weeks |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Goal of no alcohol reinforced |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Completed today | Two sessions so far |
| Medication safety | Medication for alcohol use disorder | Offered for alcohol use disorder | Not indicated | Not wanted; doing well with counseling |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Two-month review with sputum culture and liver tests. Next scheduled visit 2026-04-14: end of the intensive phase: two-month sputum and the start of the continuation phase. [S]